Compare · BCAX vs JNJ
BCAX vs JNJ
Side-by-side comparison of Bicara Therapeutics Inc. (BCAX) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCAX and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $558.86B, about 423.2x BCAX ($1.32B).
- Over the past year, BCAX is up 76.4% and JNJ is up 49.6% - BCAX leads by 26.8 points.
- JNJ has been more active in the news (8 items in the past 4 weeks vs 6 for BCAX).
- JNJ has more recent analyst coverage (25 ratings vs 15 for BCAX).
- Company
- Bicara Therapeutics Inc.
- Johnson & Johnson
- Price
- $20.11+0.53%
- $232.15-0.24%
- Market cap
- $1.32B
- $558.86B
- 1M return
- -12.95%
- +4.36%
- 1Y return
- +76.36%
- +49.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 6
- 8
- Recent ratings
- 15
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest BCAX
- SEC Form 144 filed by Bicara Therapeutics Inc.
- Chief Financial Officer Hyep Ivan exercised 9,200 shares at a strike of $3.79 and sold $187,883 worth of shares (9,200 units at $20.42) as part of a pre-agreed trading plan (SEC Form 4)
- Bicara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
- Chief Executive Officer Mazumdar Claire exercised 15,000 shares at a strike of $3.79 and sold $300,579 worth of shares (15,000 units at $20.04) as part of a pre-agreed trading plan (SEC Form 4)
- President and COO Cohlhepp Ryan exercised 8,000 shares at a strike of $3.79 and sold $253,649 worth of shares (12,500 units at $20.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,641 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Bicara Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research